Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
BioNTech pays $800M to take control of potential Keytruda killer
BioNTech is paying $800 million upfront to buy Biotheus and secure full rights to a leading prospect in the white-hot PD-L1xVEGF-A bispecific space.
Nick Paul Taylor
Nov 13, 2024 6:45am
Evotec attracts private equity buyout interest: report
Nov 11, 2024 9:17am
AlloVir finds new identity via eye disease biotech merger
Nov 8, 2024 9:05am
Boston Scientific bolsters pulsed field ablation with Cortex buy
Nov 4, 2024 11:00am
Jade pockets Aerovate in reverse merger
Oct 31, 2024 3:03pm
AbbVie inks $1.4B Aliada buyout to land ex-J&J Alzheimer's drug
Oct 28, 2024 10:00am
